# A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

> **NCT01013753** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 198 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** Olodaterol (BI 1744) high
- **DRUG:** Olodaterol (BI 1744) medium
- **DRUG:** Olodaterol (BI 1744) very low
- **DRUG:** Formoterol 12 mcg
- **DRUG:** Olodaterol (BI 1744) low

## Key facts

- **NCT ID:** NCT01013753
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013753, "A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01013753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*